Barclays raised the firm’s price target on Alignment Healthcare (ALHC) to $8 from $7 and keeps an Underweight rating on the shares post the Q3 report. The firm says higher medical loss ratio guidance on new member growth and clinical initiatives drove a modest 2024 EBITDA guidance reduction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare sees FY24 revenue $2.67B- 2.68B, consensus $2.63B
- Alignment Healthcare reports Q3 EPS (14c), consensus (14c)
- Alignment Healthcare sees Q4 revenue $663M-$678M , consensus $660.89M
- Alignment Healthcare options imply 13.4% move in share price post-earnings
- ALHC Upcoming Earnings Report: What to Expect?